Back to Search
Start Over
Lipid profile and long-term outcome in premature myocardial infarction.
- Source :
-
European journal of clinical investigation [Eur J Clin Invest] 2018 Oct; Vol. 48 (10), pp. e13008. Date of Electronic Publication: 2018 Aug 13. - Publication Year :
- 2018
-
Abstract
- Background: Premature myocardial infarction (≤40 years) represents a rare disease with a distinct risk factor profile and a lipid phenotype that is characterized by a predominance of elevated triglyceride-rich lipoproteins. So far high-density and low-density lipoproteins remain the primary targets for risk stratification and treatment evaluation in coronary artery disease, but this strategy might be insensitive in patients with premature myocardial infarction.<br />Aim: Aim of this study was to investigate the predictive value of different lipid fractions on long-term cardiovascular outcome in patients with premature myocardial infarction.<br />Methods: We prospectively enrolled 102 consecutive AMI survivors (≤40 years) in this prospective multicentre study and investigated the influence of the familial combined hypercholesterolaemia phenotype and a corresponding multimarker panel of different lipid fractions on cardiovascular outcome.<br />Results: Total cholesterol, non-HDL cholesterol, remnant cholesterol and Apo B lipoprotein were significantly higher in patients experiencing MACE as compared to those who did not. The familial combined hypercholesterolaemia phenotype was associated with an unfavourable cardiovascular outcome even after adjustment for potential cofounders (adjusted HR 3.04,95% CI, 1.26-7.34, P = 0.013). Remnant cholesterol revealed the strongest association with MACE (adj.HR 1.94, 95%CI. 1.30-2.99, P = 0.001). Interestingly LDL and HDL revealed no significant impact on cardiovascular outcome in this study cohort.<br />Conclusion: Non-HDL and remnant cholesterol are strongly associated with an unfavourable outcome in patients with premature myocardial infarction and might be the preferred treatment target for lipid-lowering therapy.<br /> (© 2018 Stichting European Society for Clinical Investigation Journal Foundation.)
- Subjects :
- Adult
Apolipoproteins B metabolism
Australia epidemiology
Case-Control Studies
Cholesterol, HDL metabolism
Female
Humans
Hyperlipoproteinemia Type II blood
Hyperlipoproteinemia Type II mortality
Male
Myocardial Infarction mortality
Prospective Studies
Risk Assessment
Hyperlipoproteinemia Type II complications
Lipid Metabolism physiology
Myocardial Infarction blood
Subjects
Details
- Language :
- English
- ISSN :
- 1365-2362
- Volume :
- 48
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- European journal of clinical investigation
- Publication Type :
- Academic Journal
- Accession number :
- 30062727
- Full Text :
- https://doi.org/10.1111/eci.13008